UK Markets close in 1 hr 11 mins

Genfit SA (GNFTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.12000.0000 (0.00%)
As of 09:30AM EDT. Market open.

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • S
    what a scam going down on FDA approval
  • I
    Crypto currency as we all know have been changing lives since many years back, and as a beginner which I am I was very afraid to invest in crypto but however I’ve been reading about it. Few months ago I came across a post about Mr Benjamin Richard
     who is a professional trader with his help and signals I made 7.5BTC and 40Eth. contact him via Te~le~gram~~~ @ Benjamin_Richard2
  • B
    GNFT should be up to $10 on this new deal. It's giving them around $500 million in cash and milestones, and they get 20% of the revenue from the sales of the commercialization. That's a large amount of cash, probably will end up being around $1 billion in cash. Not sure why they only added $2 to the stock price today.
  • A
    Very quiet board...

    Sometimes, still waters run deep :-)

    Anyone looking at Genfit and elafibranor for the first time (bearing in mind that the Big catalyst is the phase 3 readout in late 2019) might like to know that elafibranor was recently awarded Breakthrough Therapy status in PBC.

    Also, Barclays initiates coverage on 224 at Overweight with a PT of 55 USD (120% upside)
  • A
    12/19/2019 Show Full StoriesSend Info

    GNFT09:10 Genfit analyst commentary at Roth Capital 

    Roth says Genfit 'unlocking the power' of non-invasive diagnosis of NASH. Roth Capital analyst Yasmeen Rahimi said there is an "urgent need" for non-invasive testing in non-alcoholic steatohepatitis, or NASH, and her call with Donna Cryer of the Global Liver Institute, and Dr. Suneil Hosmane, Genfit's EVP and Global Head of Diagnostics, provided a better view into the utility and diagnostic value of the company's NIS4 NIT toolkit, which combines four biomarkers to diagnose fibrosis with high predictability. The analyst, who sees Genfit "unlocking the power of non-invasive NASH diagnosis," keeps a Buy rating and EUR70 price target on the company's shares following her expert call.
  • J
    Analysts just upgraded with 120% upside

    Check out GNFT Analyst Price Target $11.81 on TipRanks
  • G
    I'm long and lonely here. From pre-NASH collapse days. Unusual volume here yesterday and today so far.
  • a
    Nicolaus analyst Derek Archila has a hold rating on GNFT, arguing that the stock is now likely to remain range bound until management provides an update in the fall for elafibranor in NASH.
    However, there is a glimmer of hope- elafibranor’s program in primary biliary cholangitis (PBC). Archila thinks here GNFT has solid proof-of-concept data from both an efficacy and safety perspective, and that this could provide a floor for shares.
  • D
    Very strange
    Nasdaq price continuously above Euro price for the last days
  • A
    See Forbes article today: Is Genfit Primed to Win the NASH Derby?
  • s
    120 Euros = $135.6Mil in cash upfront.

    That's $3.30 per share. Stock is only up $2 on the news. Up $3.30, that would have a share price of at the very least, $6.60 per share.

    Add the 28Mil Euro ($31,600,000) investment for 3,985239 shares (or $7.94 per share) and this company should have a share price of at least $6.70.

    Very undervalued here considering the promising future with this deal.
  • T
    Terminal Gravity
    This company is starting to interest me. Recent disappointment but trading below cash. Surely their IP is worth something? Also, technicals are showing an uptick in MFI and MACD just went positive.
  • H
    I'm trying to research this company

    I see A positive article about earnings on April 17

    is elafibranor a factor in the earnings from their other operations?

    I'm assuming they will continue to operate in these other areas albeit interrupted by the Pandemic.

    What Say you?
  • A
    Genfit licenses elafibranor development and commercialization for the Greater China region.

    (Article complete with amusing analyst commentary that confuses NASH with steatosis)
    Fresh off the high of its Nasdaq IPO debut, and the low of comparisons to Cymabay — whose NASH drug recently stumbled — Genfit on Monday unveiled an up to $228 million deal with transpacific biotech Terns Pharmaceuticals to develop its flagship exper
    Fresh off the high of its Nasdaq IPO debut, and the low of comparisons to Cymabay — whose NASH drug recently stumbled — Genfit on Monday unveiled an up to $228 million deal with transpacific biotech Terns Pharmaceuticals to develop its flagship exper
  • b
  • T
    The company should look into doing a collab work with Galt. A combo therapy for F5-F6. A perfect partnership for NASH awaits and a chance for both to corner all spectrums Fibrosis as a combo therapy.
  • C
    Kepler Cheuvreux 20/2 : "Elafibranor remains the only drug in late stage development that is effective against NASH symptoms, which might make it the backbone therapy for NASH"
  • G
    6 times average volume, up 12.36% on the day and nobody even notices here.
    This is where money big time is about to be made and I have the floor all to myself.
  • s
    Stay out of this for 1-3 weeks. It's tempting because of price fall but past prices do not matter...

    Considering low trading volume, it will take a while for all the sellers to get out...

    You have been warned!

    Been there and done that...

    Good Luck to all and do your due diligence always...